PHS
PFM Health Sciences Portfolio holdings
AUM
$1.15B
This Quarter Return
+6.54%
1 Year Return
+21.39%
3 Year Return
+130.75%
5 Year Return
+265.32%
10 Year Return
+1,236.5%
AUM
$3.11B
AUM Growth
+$3.11B
(+8.3%)
Cap. Flow
+$91.8M
Cap. Flow
% of AUM
2.96%
Top 10 Holdings %
Top 10 Hldgs %
37.14%
Holding
93
New
12
Increased
19
Reduced
13
Closed
9
Top Buys
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$76.3M |
| 2 |
Centene
CNC
|
$37.3M |
| 3 |
Acadia Pharmaceuticals
ACAD
|
$36.7M |
| 4 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
$23.6M |
| 5 |
Guardant Health
GH
|
$21.1M |
Top Sells
| 1 |
PPD
PPD, Inc. Common Stock
PPD
|
$41.5M |
| 2 |
AstraZeneca
AZN
|
$36M |
| 3 |
Insulet
PODD
|
$30.9M |
| 4 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$29.1M |
| 5 |
Gilead Sciences
GILD
|
$28.1M |
Sector Composition
| 1 | Healthcare | 94.1% |
| 2 | Financials | 0.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALXN
1
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $166M | 5.19% | 901,441 -158,190 | -15% | -$29.1M |
|
|
HZNP
2
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $149M | 4.66% | 1,587,348 | – | – |
|
3
Outset Medical
OM
$247M
| $148M | 4.65% | 2,966,712 -45,997 | -2% | -$2.3M |
|
4
Eli Lilly
LLY
$657B
| $121M | 3.78% | 525,455 | – | – |
|
5
Neurocrine Biosciences
NBIX
$13.8B
| $109M | 3.4% | 1,116,004 +60,494 | +6% | +$5.89M |
|
6
AbbVie
ABBV
$372B
| $104M | 3.27% | 926,823 | – | – |
|
7
Arcus Biosciences
RCUS
$1.13B
| $96.1M | 3.01% | 3,498,260 | – | – |
|
8
Myriad Genetics
MYGN
$593M
| $94.5M | 2.96% | 3,089,152 +370,529 | +14% | +$11.3M |
|
9
IQVIA
IQV
$32.4B
| $86.7M | 2.72% | 357,916 | – | – |
|
10
HCA Healthcare
HCA
$94.5B
| $80.7M | 2.53% | 390,507 | – | – |
|
|
SGEN
11
DELISTED
Seagen Inc. Common Stock
SGEN
| $76.3M | 2.39% | +482,985 | New | +$76.3M |
|
|
12
Centene
CNC
$14.3B
| $76.2M | 2.39% | 1,045,473 +511,806 | +96% | +$37.3M |
|
13
Avantor
AVTR
$9.18B
| $73.8M | 2.31% | 2,079,657 -150,000 | -7% | -$5.33M |
|
14
Universal Health Services
UHS
$11.6B
| $71.3M | 2.24% | 487,000 | – | – |
|
|
NVRO
15
DELISTED
NEVRO CORP.
NVRO
| $69.4M | 2.18% | 418,645 -26,232 | -6% | -$4.35M |
|
|
16
Acadia Pharmaceuticals
ACAD
$4.38B
| $68.5M | 2.15% | 2,807,310 +1,505,181 | +116% | +$36.7M |
|
17
McKesson
MCK
$85.4B
| $68.1M | 2.14% | 356,231 | – | – |
|
18
Humana
HUM
$36.5B
| $63M | 1.98% | 142,406 | – | – |
|
19
UnitedHealth
UNH
$281B
| $58.2M | 1.82% | 145,295 | – | – |
|
20
Edwards Lifesciences
EW
$47.8B
| $53.1M | 1.67% | 513,005 | – | – |
|
21
ICU Medical
ICUI
$3.15B
| $52.6M | 1.65% | 255,708 -34,953 | -12% | -$7.19M |
|
22
Danaher
DHR
$147B
| $47.1M | 1.48% | 175,690 | – | – |
|
|
23
Guardant Health
GH
$8.41B
| $46.5M | 1.46% | 374,131 +169,787 | +83% | +$21.1M |
|
|
MRTX
24
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $46.4M | 1.45% | 287,046 -22,734 | -7% | -$3.67M |
|
|
25
Gilead Sciences
GILD
$140B
| $45.9M | 1.44% | 666,601 -408,462 | -38% | -$28.1M |
|